Cancer Treatment with Radioactive Labeled Antibodies

  • G. L. DeNardo
  • S. J. DeNardo
  • D. J. Macey
Conference paper


The potential of radioimmunotherapy based upon monoclonal antibodies has elicited considerable excitement within the scientific community. This type of disease targeting has been a long-standing goal of medicine. Bale [1] explored the use of polyclonal antibodies produced against fibrin and labeled with I-131 to deliver radiation therapy to tumors more than 20 years ago. The potential usefulness of this approach has been demonstrated [2], but success was limited by inadequate specificity of these polyclonal antibodies. The superiority of monoclonal antibodies over conventional polyclonal antisera has been demonstrated [3]. Monoclonal antibodies are uniquely attractive targeting molecules. Two other technological developments have occurred at precisely the same time as the hybridization technology for producing monoclonal antibody so that the simultaneous collision of these three technologies provides a unique opportunity for provision of radionuclide therapy based upon not only the specificity of monoclonal antibodies, but also treatment planning techniques of the type which have proved necessary in external beam and radionuclide sealed source radiation therapy. Contrary to common misconception, radionuclide therapy does not necessarily require more favorable target to nontarget relationships than radionuclide imaging. The critical element for radionuclide therapy is the nature of the nontarget or critical organ and its radiosensitivity.


Linear Energy Transfer Radionuclide Therapy Maximum Dose Rate Avid Tumor Radiat Oncol Bioi Phys 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bale WF, Spar IL, Goodland RL (1960) Experimental radiation therapy of tumors with 131I-carrying antibodies to fibrin. Cancer Res 20:1488–1494PubMedGoogle Scholar
  2. 2.
    Spar IL, Bale WF, Marrack D, Dewey WC, McCardle RJ, Harper PV (1967) 131I-labeled antibodies to human fibrinogen: diagnostic studies and therapeutic trials. Cancer 20:865–870PubMedCrossRefGoogle Scholar
  3. 3.
    DeNardo GL, DeNardo SJ (1983) Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer. In: Burchiel SW, Rhodes BA (eds) Radioimmunoimaging and radioimmunotherapy. Elsevier, New York, pp 41–60Google Scholar
  4. 4.
    Brady LW, Order SE, Leigel SA, Markoe AM (1984) Radionuclides for systemic on-cotherapy. Cancer Treat Symp 1:127–134Google Scholar
  5. 5.
    DeNardo GL, Raventos A, Hines HH, Scheibe PO, Macey DJ, Hays MT, DeNardo SJ (1985) Requirements for a treatment planning system for radioimmunotherapy. Int J Radiat Oncol Biol Phys 11:335–348PubMedCrossRefGoogle Scholar
  6. 6.
    Leichner PK, Klein JL, Garrison JB, Jenkins RE, Nickoloff EL, Ettinger DS, Order SE (1981) Dosimetry of 131I-labeled antiferritin in hepatoma: A model for radioimmunoglobulin dosimetry. Int J Rad Oncol Biol Phys 7:323–333CrossRefGoogle Scholar
  7. 7.
    Carrasquillo JA, Krohn KA, Beaumier P, McGuffin RW, Brown JP, Hellstrom KE, Hellstrom I, Larson SM (1984) Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 68:317–328PubMedGoogle Scholar
  8. 8.
    Order SE (1982) Monoclonal antibodies: potential role in radiation therapy and oncology. Int J Rad Oncol Biol Phys 8:1193–1201Google Scholar
  9. 9.
    Boone CW, Brandchaft PR, Irving DN, Gilden R (1972) Quantitative studies on the binding of syngeneic antibody to the surface antigens of AKR virus-induced rat lymphoma cells. Int J Cancer 9:685–692PubMedCrossRefGoogle Scholar
  10. 10.
    McGaughey C (1974) Feasibility of tumor immunoradiotherapy using radioiodinated antibodies to tumor-specific cell membrane antigens with emphasis on leukemias and early metastases. Oncology 29:302–319PubMedCrossRefGoogle Scholar
  11. 11.
    Wessels BW, Rogus RD (1984) Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 11:638–645PubMedCrossRefGoogle Scholar
  12. 12.
    DeNardo SJ, Jungerman JA, DeNardo GL, Lagunas-Solar MC, Cole WC, Meares CF (1984) The choice of radionuclides for radioimmunotherapy. In: The developing role of short-lived radionuclides in nuclear medicine practice. Oak Ridge, Tennessee, Department of Energy Technical Information Center, CONF-82-523, NTIS, pp 396–409Google Scholar
  13. 13.
    Rostock RA, Klein JL, Kopher KA, Order SE (1984) Variables affecting the tumor localization of 131I-antiferritin in experimental hepatoma. Am J Clin Oncol (CCT) 6:9–18CrossRefGoogle Scholar
  14. 14.
    Rostock RA, Klein JL, Leichner P, Kopher KA, Order SE (1983) Selective tumor localization in experimental hepatoma by radiolabeled antiferritin antibody. Int J Radiat Oncol Biol Phys 9:1345–1350PubMedCrossRefGoogle Scholar
  15. 15.
    Noltenius HW (1981) Fc and complement receptors on malignant tumor cells. Cancer 48:1761–1767PubMedCrossRefGoogle Scholar
  16. 16.
    Leichner PK, Koein JL, Siegelman SS, Ettinger DS, Order SE (1983) Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver. Cancer Treat Rep 67:647–658PubMedGoogle Scholar
  17. 17.
    Larson SM, Carrasquillo JA, Krohn KA et al. (1983) Localization of 131I-labeled p97-spe- cific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 72:2101–2114PubMedCrossRefGoogle Scholar
  18. 18.
    Brown JP, Nishiyamau K, Hellstrom I et al. (1981) Structural characterization of human melanoma-associated antigen p97 using monoclonal antibodies. J Immunol 127:539–546PubMedGoogle Scholar
  19. 19.
    Brown JP, Hemwick RM, Hellstrom I et al. (1982) Human melanoma-associated antigen is structurally and functionally related to transferrin. Nature 296:171–173PubMedCrossRefGoogle Scholar
  20. 20.
    Hellstrom I, Garrigues J, Cabasco L et al. (1983) Studies of a high molecular weight human melanoma-associated antigen. J Immunol 130:1467–1472PubMedGoogle Scholar
  21. 21.
    DeNardo SJ, Erickson KL, Benjamini E (1980) Use of I-131 antibodies for radiation therapy. Clin Nucl Med 5:9 SGoogle Scholar
  22. 22.
    DeNardo SJ, Erickson KL, Benjamini E, Hines H, Scibeinski R (1981) Radioimmunotherapy for melanoma. Clin Res 29Google Scholar
  23. 23.
    DeNardo SJ, Erickson K, Benjamini E, Hines H, Scibienski R, DeNardo G (1982) Monoclonal antibodies for radiation therapy of melanoma. In: Raynaud C (ed) Nuclear medicine and biology. Pergamon, Paris, pp 182–185Google Scholar
  24. 24.
    DeNardo SJ, Hines HH, Erickson KL, DeNardo GL (1983) Evaluation of radiolabeled monoclonal antibody parameters necessary for cancer immunotherapy. In: Chabner BA (ed) Rational basis for chemotherapy. Liss, New York, pp 379–387Google Scholar
  25. 25.
    Adams DA, DeNardo GL, DeNardo SJ (1984) In vivo monitoring of RIT in lymphoma by quantitation of phosphate metabolites with P-31 NMR. Clin Nucl Med 9(9S):P33CrossRefGoogle Scholar
  26. 26.
    Epstein AL, Zimmer AM, Spies SM, Mills SL, DeNardo GL, DeNardo SJ (1984) Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1). Proceedings of the 2nd International conference on malignant lymphoma. Nijhoff, BostonGoogle Scholar
  27. 27.
    Cole W, DeNardo SJ, Meares C, DeNardo G, O’Brien H (1983) Development of copper- 67 chelate conjugated monoclonal antibodies for radioimmunotherapy. J Nucl Med 24(5):P30Google Scholar
  28. 28.
    DeNardo GL, DeNardo SJ, Peng J-S, O’Grady LF, Cardiff RD, Mills SL (1984) Effects of protein mass on the pharmacokinetics of monoclonal antibodies. Clin Nucl Med 9(9S):P37CrossRefGoogle Scholar
  29. 29.
    Kassis AI, Adelstein SJ, Haydock C, Sastry KSR, McElvany KD, Welch MJ (1982) Lethality of auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res 90:362–373PubMedCrossRefGoogle Scholar
  30. 30.
    Gullberg GT (1979) The attenuated Radon transfer: theory and application in medicine and biology. Ph. D. Thesis, University of California, Berkeley, LBL 7486CrossRefGoogle Scholar
  31. 31.
    Macey DJ, Marshall R (1982) Absolute quantiation of radiotracer uptake in the lungs using a gamma camera. J Nucl Med 23:731–734PubMedGoogle Scholar
  32. 32.
    Epenetos AA (1984) Antibody-guided irradiation of malignant lesions: three cases illustrating a method of treatment. Lancet: 1441–1443Google Scholar
  33. 33.
    Barth RF, Johnson CW, Wei W-Z, Carey WE, Soloway AH, McGuire J (1982) Neutron capture using boronated monoclonal antibody directed against tumor-associated antigens. Cancer Detect Prev 5:315–323PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • G. L. DeNardo
    • 1
  • S. J. DeNardo
  • D. J. Macey
  1. 1.Davis, School of Medicine, Division of Nuclear MedicineUniversity of CaliforniaSacramentoUSA

Personalised recommendations